IMMUNITYBIO, INC. (IBRX)

Every figure this model derived for IBRX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 6,936,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 357,371,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 438,980,000 AssetsCurrent 2026-06-30
current liabilities 76,727,000 LiabilitiesCurrent 2026-06-30
equity -1,046,629,000 StockholdersEquity 2026-06-30
interest expense 76,941,000 InterestPaidNet 2026-06-30
ocf -281,138,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 165,792,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 34,311,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up IBRX on one particular measure came for.

RatioValue
cash operating margin-121.17
current ratio5.72
current ratio reported5.72
deferred revenue growth66.67
dilution pct31.35
fcf margin-173.76
growth cv1.41
interest cover-3.27
operating margin-151.88
owner earnings margin-194.45
revenue growth192.92
revenue growth per share123.01
rule of 4041.04
sbc pct revenue20.7

What to be careful about

What this model itself distrusts about IBRX's figures. Written by the derivation as it ran, not added afterwards.